Episurf Medical provides update on process for UK NICE guidelines

Episurf Medical (NASDAQ: EPIS B) today provides an update on the work related to the UK National Institute for Health and Care Excellence’s (NICE) guidelines. NICE guidelines are evidence-based recommendations for health and care in the UK, to help healthcare professionals in their work. The guidelines also support payors and authorities on their decisions to reimburse various procedures and devices. Episurf Medical has participated in several NICE hearings for its Episealer® knee implant family, and the company has been informed about the timetable, which is likely to result in guidelines being published during August 2022.

“This has been a long and very important process for us. We hope to see the final guidelines being published soon, and we hope that this will support our continuous commercial efforts in the UK market”, says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.